Product name
Allo-HLA-A2 restricted peptide specific T cells show specific cytotoxicity against malignant cell linesSummary
A T cell receptor recognizing antigenic peptides derived from tumorassociated antigen FMNL1 and capable of inducing peptide specific killing of a target cellOrganization name
Ascenion GmbHProfile
The incidence of B cell neoplasms is increasing world wide. In chronic lymphocytic leukaemia (CLL), still no established curative therapy is available at any point of diagnosis.
For patients with progressing CLL, treatment with conventional doses of chemotherapy is not curative; selected patients treated with allogeneic stem cell transplantation have achieved prolonged disease-free survival.
Immunotherapy has been shown to be highly successful in low grade lymphoma. Target specific therapies using monoclonal antibodies against CD20 (Rituximab) or CD52 (Alemtuzumab) are only partially efficient because of tumor escape due to down regulation of the target antigens from the cell surface.
The Technology
A T cell receptor (TCR) recognizing antigenic peptides derived from tumor-associated antigen FMNL1 and capable of inducing peptide specific killing of a target cell is provided.
FMNL1 is a formin related protein in leukocytes which is highly expressed in >60% of CLL samples tested and aberrantly expressed in transformed cell lines of various tissues. Allo-HLA-A2 restricted peptide specific T cells have been generated which show specific cytotoxicity against malignant cell lines derived from various tumors, including CLL.
Commercial Benefit
The allorestricted FMNL1 peptide-specific T cells will be helpful for the development of efficient immunotherapies against malignant lymphoma, especially CLL, and other malignancies. Those T cells bearing TCR which have the capacity to recognize their MHC-peptide ligand on the tumor cells can be used for treating patients with significantly reduced risk of graft-versus-host-disease (GVHD).
Development Status
In vitro cell culture
Commercial Opportunity
License is offered worldwide, exclusive (non-exclusive); further cooperation is desired. A European patent application has been filed.
Contact
Dr. Hubert Mueller
mueller@ascenion.de
About Ascenion
Ascenion is the exclusive partner of 12 life-science institutes in the Helmholtz and Leibniz Associations and of one Medical School, and coordinates technology transfer for the German National Genome Research Network. They currently market around 600 technologies, together with a varied range of research materials, e.g. antibodies, animal models and vectors.
Description File
TO_01-00717_01.pdf
print this page
